On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
FridaySep 25, 2020 1:14 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is “One to Watch”

CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit. In preclinical studies, the company’s second drug candidate, a novel DNA binding agent, was 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Industry reports estimate that the global brain…

Continue Reading

FridaySep 25, 2020 12:35 pm

Pac Roots Cannabis Corp. (CSE: PACR) Leverages Expertise, Resources to Establish Dominant Position in Growing Cannabis Market

Legal marijuana market set to top more than $90 billion by 2027 Pac Roots places top priority on developing, delivering finest cannabis genetics Optimized farming systems employed in most fertile areas means maximum opportunity for harvest After experiencing a few roadblocks over the last year, the cannabis sector looks to be picking up speed. In fact, a recent Data Bridge Market Research study reports that the global legal marijuana market should top more than $90 billion by 2027 (https://ibn.fm/UE8Tj). Pac Roots Cannabis (CSE: PACR), a Canadian company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach, has taken…

Continue Reading

FridaySep 25, 2020 11:48 am

180 Life Sciences Corp. Leading Research into Novel Drug Therapies Expected to Produce First Results of Phase 2b/3 Trial in 2021

Anti-inflammatory therapeutics market to generate revenues of $191.42 billion through 2027 Novel drug therapy for Fibrosis and Anti-TNF trials being conducted by Professor Sir Marc Feldmann, who already developed one of the most commonly used anti-TNF medications, Remicade The number of conditions with chronic inflammation is expected to increase persistently over the next 30 years in the United States. 180 Life Sciences is in the process of being acquired by KBLM Merger Corp. and the acquisition is expected to finalize in Q4 2020 Clinical-stage biotechnology company 180 Life Sciences Corp. is leading the way with research into the world’s most…

Continue Reading

FridaySep 25, 2020 10:58 am

The Movie Studio Inc. (MVES) Making Major Moves in Growing Streaming Market

Streaming sites are among businesses that have seen an uptick in sales during worldwide pandemic Content key for companies in streaming space The Movie Studio moving forward in space, expanding content and keeping costs down Not all businesses are struggling through the worldwide pandemic. A recent CompariTech article reported that streaming video is becoming a viable option for a growing number of viewers around the world, resulting in increasing numbers for companies involved in streaming content (https://ibn.fm/wSNni). The Movie Studio (MVES), a vertically integrated motion picture production and distribution company, is looking to become a major player in this star-studded…

Continue Reading

ThursdaySep 24, 2020 2:08 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Inks Major Contract; Skyline Medical Seals STREAMWAY Deal

POAI’s Soluble Biotech announces first substantial contract with pharmaceutical company since acquisition Founder calls contract “major milestone,” validation of move into new facility POAI’s Skyline Medical sells eight proprietary STREAMWAY(R) systems to Virginia-based hospital organization Soluble Biotech, a division of Predictive Oncology (NASDAQ: POAI), has finalized its first substantial contract with a pharmaceutical company since being acquired by POAI earlier this year (https://ibn.fm/gXjd2). Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. The contract calls for Soluble Biotech’s expertise in protein expression and solubility studies. “Our first…

Continue Reading

ThursdaySep 24, 2020 12:44 pm

In Wake of Hurricane Laura, Sustainable Green Team Ltd. (SGTM) Plays Pivotal Role in Relief Support

SGTM secures Hurricane Laura recovery work contract for ArborPro of Mississippi Inc. Initial relief efforts will divert trees from landfills to temporary holding sites SGTM transforms natural storm waste into organic environmentally beneficial products As “stewards of the environment”, Sustainable Green Team (OTC: SGTM) takes its role in environmental remediation seriously by providing beneficial solutions for tree and storm waste disposal. In the wake of Hurricane Laura, SGTM rose to the occasion by securing a contract for ArborPro of Mississippi Inc. (APM), one of its strategic partners. The recovery work planned will kickstart SGTM’s process, diverting many destroyed trees from…

Continue Reading

ThursdaySep 24, 2020 10:28 am

Trxade Group Inc. (NASDAQ: MEDS) Pharmaceutical Supply Chain Trading Platform Gives Independent Drugstores a New Lease on Life

Pressing need for efficient drug procurement, delivery as costs rise Trxade platform speeds up delivery, cuts costs Such efficiencies crucial to keeping America’s independent pharmacies alive Around half of 24,000 independent pharmacies have already signed on These days, critics of the U.S. health-care system may be tempering their censure. After all, the sector has proved its worth in the battle against the coronavirus pandemic. Yet some of the fault-finding had merit. The system is bloated and plagued by inefficiencies. Even doctors agree, as a recent report in the “Journal of the American Medical Association” (“JAMA”) indicates (https://ibn.fm/bL7C1). Digital technologies may help…

Continue Reading

WednesdaySep 23, 2020 2:33 pm

Kaival Brands Innovations Group Inc. (KAVL) Seeks to Bring Innovative New Offering to Vape Scene

KAVL recently announced the Bidi(TM) Vapor Premarket Tobacco Product Application submission to FDA, a premium recyclable vape pen Application includes 285,000 pages with science-backed evidence that Bidi(TM) Sticks are Appropriate for Protection of Public Health (“APPH”) KAVL and Bidi(TM) Vapor fully support proper regulation of safety manufacturing and marketing of vape products Bidi(TM) Sticks are produced in 11 flavors with 6% nicotine concentration With a focus on growing and incubating innovative products into mature dominant brands, Kaival Brands Innovations Group (OTCQB: KAVL) recently entered into a partnership with Bidi (TM) Vapor, LLC for exclusive global distribution rights for the Bidi(TM)…

Continue Reading

WednesdaySep 23, 2020 2:07 pm

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) Trades on OTCQB, Creating Early Opportunity for American Investors

GoldHaven to trade on OTCQB under ticker symbol ATUMF Move provides liquidity in trading of shares, creates opportunity for American investors to participate in Maricunga Gold Belt activity GoldHaven recently entered into agreements to acquire seven gold projects, plans aggressive drill program GoldHaven Resources (CSE: GOH) (OTCQB: ATUMF), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, has announced that it has been accepted for trading on the OTCQB (https://ibn.fm/fB9Z3). The OTCQB exchange is a United States stock market based in New York City and operated by OTC Markets Group. The shares will trade on OTCQB…

Continue Reading

WednesdaySep 23, 2020 1:51 pm

United Bid to Liberalize Use of Psilocybin Strengthens

Leading UK scientists, policy group call for rescheduling of psilocybin amid looming mental health crisis Sent to the Home Office with statements of support from leading scientists, paper urges for psilocybin use on a research-only model Cybin Corp. to capitalize on international expansion of psilocybin use as a company active in both research, nonclinical spaces The United Kingdom (“UK”) is joining other countries, including Canada, in a push to facilitate the wider use of psilocybin, a naturally occurring compound found in mushrooms. Focusing on psychedelic and nutraceutical products, Cybin Corp. is poised to leverage the growing global momentum the compound is…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.


Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered